Integrated BioPharma Reports 27.5% Decline in Q3 Revenue, Net Loss of $837,000

Integrated BioPharma, Inc. reported a significant decline in financial performance for the third quarter of fiscal year 2026, ending March 31, 2026. The company recorded net sales of $10.1 million, a decrease of 27.5% from $13.9 million in the same quarter of the previous year. For the nine-month period, net sales fell to $34.1 million, down 15.2% from $40.2 million. The decline was attributed primarily to reduced sales volumes from key customers, particularly in the Contract Manufacturing Segment, which saw a drop of approximately 14%. The company also reported a net loss of $837,000 for the quarter, compared to a net income of $611,000 in the prior year.

The company's cost of sales for the quarter was $10.4 million, resulting in a gross loss of $276,000, contrasting with a gross profit of $1.6 million in the same quarter last year. The increase in cost of sales as a percentage of net sales rose to 102.7%, indicating that fixed manufacturing costs were not sufficiently offset by sales revenue. Selling and administrative expenses remained relatively stable at $809,000, slightly down from $812,000 in the prior year. The overall operating loss for the quarter was $1.1 million, compared to an operating income of $739,000 in the same quarter of the previous year.

In terms of operational metrics, Integrated BioPharma's customer concentration remains high, with approximately 90% of consolidated net sales derived from two major customers in the Contract Manufacturing Segment. This dependency poses a risk, as any loss of these customers could significantly impact the company's financial health. The company also reported a decrease in accounts receivable and inventories, which contributed to a net cash provided by operating activities of $2.4 million for the nine months ended March 31, 2026, compared to $1.5 million in the same period last year.

Looking ahead, Integrated BioPharma is focusing on improving operational efficiency and reducing costs to enhance its gross margins. The company is also exploring opportunities to expand its customer base to mitigate reliance on its major clients. However, challenges such as inflation, tariffs, and tightened labor markets may hinder its ability to increase selling prices in line with rising operational costs. The company has cash reserves of $5.8 million and access to credit lines totaling approximately $4.5 million, which management believes will support working capital needs through at least May 2027.